ClinicalTrials.gg
CompletedNCT05344729Updated Apr 25, 2022

Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects

A Phase 1 interventional study of TQB3616 Capsule in Recurrent/Metastatic Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jul 2021, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing culmerciclib in Breast Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. culmerciclib · Breast Neoplasms.

Enrollment
14th of 15
16 · median 40
Started
2021
with 1 other
Phase 1
3 of 15
1 open now
Registered
3rd of 15
by date
Lead sponsor
8 of 15
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 15 studies testing culmerciclib in Breast Neoplasms, this one is the 14th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 1, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 15 studies testing culmerciclib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About culmerciclib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing culmerciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

TQB3616 capsule is a small molecule oral drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., which inhibits cyclin-dependent kinases 4 and 6 (CDK4/6). Its main mechanism of action is to inhibit the proliferation of tumor cells by reducing the phosphorylation level of retinoblastoma protein (Rb) in cancer cells and blocking the progression of cells from G1 phase to S phase. This study is a randomized, open-label, single-center, two-period, two-crossover phase I clinical trial to assess the effect of food on the pharmacokinetics of TQB3616 capsules in healthy adult subjects, to evaluate the effect of food on the pharmacokinetics of TQB3616 capsules after oral administration in healthy adult Chinese subjects and to observe the safety of TQB3616 capsules after single oral administration in healthy subjects.Each subject will be randomly assigned to one of two groups (group A and B). A total of 16 subjects were enrolled, all taking TQB3616 capsules 180mg, including 8 subjects in group A and 8 subjects in group B. The study included screening period, randomization, first cycle, washout period and second cycle. The first cycle and second cycle each contained 3 return visits. 18 pharmacokinetic samples were collected every cycle for pharmacokinetic index analysis. Vital signs, physical examinations, 12-lead electrocardiograms, clinical laboratory tests, adverse events, drug combination and non-drug therapy information were collected during the study to ensure the safety of the subjects.

03

Conditions studied

  • Recurrent/Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 Sign the form before the trial and fully understand the content, process and possible adverse reactions of the trial;
  • 2 Be able to complete the study according to the requirements of the study protocol;
  • 3 Subjects aged 18 to 65 years (including 18 and 65 years);
  • 4 (BMI) ≥ 18 and ≤ 28 kg/m2, and male body weight ≥ 50 kg Female body weight ≥ 45 kg;
  • 5 Health condition: no mental disorders, no history of cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system and metabolic abnormalities;
  • 6 Subjets had no plans to become pregnant and voluntarily took effective measures from 2 weeks before dosing to at least 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • 1 Patients with a history of neuropsychiatric, respiratory, cardiovascular, gastrointestinal, hemolymphatic, hepatic or renal insufficiency, endocrine, musculoskeletal system disease or other diseases, which may affect drug metabolism or safety as judged by the investigator;
  • 2 Allergic constitution or previous history of two or more kinds of food or drug allergy;
  • 3 Hyperactive/venous thrombotic events within 6 months, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis and pulmonary embolism;
  • 4 Patients with multiple factors affecting oral drugs (such as inability to swallow, gastrointestinal diseases);
  • 5 Taking any prescription drugs, over-the-counter drugs, vitamin products or herbal medicines within 1 month before taking the study drug;
  • 6 Administration of inhibitors or inducers within 1 month before screening or before study drug;
  • 7 Taking special diet (including grapefruit, etc.) or strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, excretion, etc. within 14 days before screening;
  • 8 Abnormal and laboratory findings during the screening period;
  • 9 Blood donation or significant blood loss (> 450 mL) within 3 months prior to administration of study drug;
  • 10 Participated in any drug clinical trial within 3 months before taking the study drug;
  • 11 Smoking more than 5 cigarettes per day within 3 months before the trial;
  • 12 Positive breath alcohol test or history of alcoholism (14 units of alcohol per week: 1 unit = 360 mL of beer or 45 mL of spirits with 40% alcohol or 150 mL of wine);
  • 13 Drug screening positive or drug use 3 months before the trial;
  • 14 Inability to tolerate venipuncture for blood sampling or poor vascular status;
  • 15 Subjets cannot complete the trial due to personal reasons;
  • 16 Other conditions considered inappropriate by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    TQB3616 Capsule- Fasted+ TQB3616 Capsule- After meal

    Subjects in Arm A will take TQB3616 capsules under fasting and fed state in Cycle 1 and Cycle 2, respectively

    Drug: TQB3616 Capsule

  • Experimental
    TQB3616 Capsule- After meal + TQB3616 Capsule- Fasted

    Subjects in Arm B will take TQB3616 capsules in Cycle 1 and Cycle 2 under fasting state, respectively

    Drug: TQB3616 Capsule

Interventions

  • It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.

06

What researchers measure

Primary outcomes

  1. Peak concentration(Cmax)

    Maximum plasma drug concentration

    Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  2. Area under the time-concentration curve from 0 to t hours after drug administration(AUC0-t))

    Area under the plasma concentration-time curve from the time of first dose to the time of the last measurable concentration

    Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  3. Area under the time-concentration curve from 0 to infinity after drug administration(AUC0-∞)

    Area under the plasma concentration-time curve from the time of first dosing extrapolated to infinity

    Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

Secondary outcomes

  1. Time to peak(Tmax)

    Time to reach maximum (peak) plasma concentration following drug administration

    Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  2. Elimination half-life(t1/2)

    Elimination half-life (to be used in one-or non-compartmental model)

    Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  3. Apparent volume of distribution(Vd/F)

    Apparent volume of distribution after non-intravenous administration

    Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  4. Apparent clearance(CL/F)

    Apparent total clearance of the drug from plasma after oral administration

    Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  5. Bioavailability(F)

    Bioavailability (systemic availability of the administered dose)

    Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  6. Elimination rate constant (λz)

    Terminal disposition rate constant/terminal rate constant

    Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  7. Body temperature

    Abnormal body temperature

    Time frame: The first and second cycles before adminisyration, 1, 2, 6, 8, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  8. Pulse

    Abnormal pulse

    Time frame: The first and second cycles before adminisyration, 1, 2, 6, 8, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  9. Blood pressure

    Abnormal blood pressure

    Time frame: The first and second cycles before adminisyration, 1, 2, 6, 8, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)

  10. Physical examination

    The doctor percusses, looks, and questions the subject

    Time frame: After the end of the first cycle and the second cycle (each cycle is 12 days)

  11. Electrocardiogram QT interval

    Safety Checks

    Time frame: After the end of the first cycle and the second cycle (each cycle is 12 days)

  12. Adverse Events

    Monitor the safety indicators of subjects during the trial

    Time frame: Up to 31 days (each cycle is 12 days)

07

Study locations

1 site
  • Affiliated Hospital of Changchun University of Traditional Chinese Medicine
    Changchun, Jilin 130021, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Aug 2021, 1 month.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 1 month is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2022
First posted
Apr 25, 2022
StartActual
Jul 6, 2021
Primary completionActual
Aug 30, 2021
CompletionActual
Aug 30, 2021
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05344729
Responsible party
Sponsor
First posted
Apr 25, 2022
Start date
Jul 6, 2021
Primary completion
Aug 30, 2021
Completion
Aug 30, 2021
Last update
Apr 25, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Culmerciclib

Start the discussion